Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: Behavioural and histopathological characterisation

Neuroscience

Volumn 114, Issue 4, 2002, Pages 1005-1017

  Fernagut, P O ^a   Diguet, E ^a   Stefanova, N ^b   Biran, M ^c   Wenning, G K ^b   Canioni, P ^c   Bioulac, B ^a   Tison, F ^a  

^a CNRS   (France)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c CNRS University Bordeaux Segalen   (France)

Author keywords

3 nitropropionic acid; Magnetic resonance imaging; Motor disorder; Mouse; Striatal lesion; Substantia nigra

Indexed keywords

3 NITROPROPIONIC ACID; METENKEPHALIN; SUBSTANCE P;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BODY POSTURE; BRADYKINESIA; CELL LOSS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINERGIC NERVE CELL; DYSTONIA; HISTOPATHOLOGY; IMMUNOREACTIVITY; IN VIVO STUDY; INTOXICATION; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION;

EID: 0036837148     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00205-1     Document Type: Article

References (56)

1. Alexi T., Hughes P.E., Knusel B., Tobin A.J. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice. Exp. Neurol. 153:1998;74-93.
2. Andreassen O.A., Ferrante R.J., Hughes D.B., Klivenyi P., Dedeoglu A., Ona V.O., Friedlander R.M., Beal M.F. Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. J. Neurochem. 75:2000;847-852.
3. Andreassen O.A., Ferrante R.J., Dedeoglu A., Albers D.W., Klivenyi P., Carlson E.J., Epstein C.J., Beal M.F. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp. Neurol. 167:2001;189-195.
4. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
5. Beal M.F. Limited-time exposure to mitochondrial toxins may lead to chronic progressive neurodegenerative diseases. Mov. Disord. 15:2000;434-435.
6. Bezard E., Boraud T., Chalon S., Brotchie J.M., Guilloteau D., Gross C.E. Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience. 103:2001;117-123.
7. Bland J.M., Altman D.G. Cronbach's alpha. Br. Med. J. 314:1997;572.
8. Bogdanov M.B., Ferrante R.J., Kuemmerle S., Klivenyi P., Beal M.F. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J. Neurochem. 71:1998;2642-2644.
9. Bogdanov M.B., Ferrante R.J., Mueller G., Ramos L.E., Martinou J.C., Beal M.F. Oxidative stress is attenuated in mice overexpressing BCL-2. Neurosci. Lett. 262:1999;33-36.
10. Borlongan C.V., Koutouzis T.K., Freeman T.B., Cahill D.W., Sanberg P.R. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res. 697:1995;254-257.
11. Borlongan C.V., Nishino H., Sanberg P.R. Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation. Neurosci. Res. 28:1997;185-189.
12. Brouillet E., Hantraye P. Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr. Opin. Neurol. 8:1995;469-473.
13. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. USA. 92:1995;7105-7109.
14. Brouillet E., Guyot M.C., Mittoux V., Altairac S., Conde F., Palfi S., Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70:1998;794-805.
15. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59:1999;427-468.
16. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19:1999;3248-3257.
17. Chalon S., Emond P., Bodard S., Vilar M.P., Thiercelin C., Besnard J.C., Guilloteau D. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse. 31:1999;134-139.
18. Chyi T., Chang C. Temporal evolution of 3-nitropropionic acid-induced neurodegeneration in the rat brain by T2-weighted, diffusion-weighted, and perfusion magnetic resonance imaging. Neuroscience. 92:1999;1035-1041.
19. Colotla V.A., Flores E., Oscos A., Meneses A., Tapia R. Effects of MPTP on locomotor activity in mice. Neurotoxicol. Teratol. 12:1990;405-407.
20. D'Hooge R., Hartmann D., Manil J., Colin F., Gieselmann V., De Deyn P.P. Neuromotor alterations and cerebellar deficits in aged arylsulfatase A-deficient transgenic mice. Neurosci. Lett. 273:1999;93-96.
21. Dulawa S.C., Grandy D.K., Low M.J., Paulus M.P., Geyer M.A. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 19:1999;9550-9556.
22. Eilam R., Peter Y., Elson A., Rotman G., Shiloh Y., Groner Y., Segal M. Selective loss of dopaminergic nigro-striatal neurons in brains of Atm-deficient mice. Proc. Natl. Acad. Sci. USA. 95:1998;12653-12656.
23. Franklin, K.B.J., Paxinos, G., 1997. The Mouse Brain in Stereotaxic Coordinates, 1st edn. Academic Press, New York.
24. Gahtan E., Auerbach J.M., Groner Y., Segal M. Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice. Eur. J. Neurosci. 10:1998;538-544.
25. Ghorayeb I., Puschban Z., Fernagut P.O., Scherfler C., Rouland R., Wenning G.K., Tison F. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp. Neurol. 167:2001;133-147.
26. Gonzalez-Lima, F., Cada, A., 1998. In: Gonzalez-Lima, F. (Ed.), Cytochrome Oxidase in Neuronal Metabolism and Alzheimer's Disease. Plenum Press, New York.
27. Goto S., Hirano A., Matsumoto S. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration. Neurology. 40:1990;1051-1056.
28. Gould D.H., Gustine D.L. Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. Neuropathol. Appl. Neurobiol. 8:1982;377-393.
29. Guilloteau D., Emond P., Baulieu J.L., Garreau L., Frangin Y., Pourcelot L., Mauclaire L., Besnard J.C., Chalon S. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β- (4′-methylphenyl)nortropane (PE2I). Nucl. Med. Biol. 25:1998;331-337.
30. Guyot M.C., Hantraye P., Dolan R., Palfi S., Maziere M., Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience. 79:1997;45-56.
31. Hickey M.A., Morton A.J. Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J. Neurochem. 75:2000;2163-2171.
32. Johnson J.R., Robinson B.L., Ali S.F., Binienda Z. Dopamine toxicity following long term exposure to low doses of 3-nitropropionic acid (3-NPA) in rats. Toxicol. Lett. 116:2000;113-118.
33. Kim G.W., Copin J.C., Kawase M., Chen S.F., Sato S., Gobbel G.T., Chan P.H. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20:2000;119-129.
34. Kim G.W., Chan P.H. Oxidative stress and neuronal DNA fragmentation mediate age-dependent vulnerability to the mitochondrial toxin, 3-nitropropionic acid, in the mouse striatum. Neurobiol. Dis. 8:2001;114-126.
35. Klivenyi P., Andreassen O.A., Ferrante R.J., Dedeoglu A., Mueller G., Lancelot E., Bogdanov M., Andersen J.K., Jiang D., Beal M.F. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci. 20:2000;1-7.
36. Korpi E.R., Koikkalainen P., Vekovischeva O.Y., Makela R., Kleinz R., Uusi-Oukari M., Wisden W. Cerebellar granule-cell-specific GABAA receptors attenuate benzodiazepine-induced ataxia: evidence from α 6-subunit-deficient mice. Eur. J. Neurosci. 11:1999;233-240.
37. Koutouzis T.K., Borlongan C.V., Scorcia T., Creese I., Cahill D.W., Freeman T.B., Sanberg P.R. Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Res. 646:1994;242-246.
38. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18:1991;492-498.
39. Lundberg C., Wictorin K., Bjorklund A. Retrograde degenerative changes in the substantia nigra pars compacta following an excitotoxic lesion of the striatum. Brain Res. 644:1994;205-212.
40. Matsuura K., Kabuto H., Makino H., Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods. 73:1997;45-48.
41. Nakao N., Brundin P. Effects of α-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience. 76:1997;749-761.
42. Ouary S., Bizat N., Altairac S., Menetrat H., Mittoux V., Conde F., Hantraye P., Brouillet E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience. 97:2000;521-530.
43. Palfi S., Ferrante R.J., Brouillet E., Beal M.F., Dolan R., Guyot M.C., Peschanski M., Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 16:1996;3019-3025.
44. Palfi S., Conde F., Riche D., Brouillet E., Dautry C., Mittoux V., Chibois A., Peschanski M., Hantraye P. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat. Med. 4:1998;963-966.
45. Pang Z., Geddes J.W. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J. Neurosci. 17:1997;3064-3073.
46. Pei G., Ebendal T. Specific lesions in the extrapyramidal system of the rat brain induced by 3-nitropropionic acid (3-NPA). Exp. Neurol. 132:1995;105-115.
47. Rondi-Reig L., Lohof A., Dubreuil Y.L., Delhaye-Bouchaud N., Martinou J.C., Caston J., Mariani J. Hu-Bcl-2 transgenic mice with supernumerary neurons exhibit timing impairment in a complex motor task. Eur. J. Neurosci. 11:1999;2285-2290.
48. Rozas G., Lopez-Martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods. 83:1998;165-175.
49. Storey E., Beal M.F. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain. 116:1993;1201-1222.
50. Urbanska E.M., Blaszczak P., Saran T., Kleinrok Z., Turski W.A. Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice. Eur. J. Pharmacol. 359:1998;55-58.
51. Waldner R., Puschban Z., Scherfler C., Seppi K., Jellinger K., Poewe W., Wenning G.K. No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). Neuroscience. 102:2001;581-592.
52. Wenning G.K., Quinn N., Magalhaes M., Mathias C., Daniel S.E. 'Minimal change' multiple system atrophy. Mov. Disord. 9:1994;161-166.
53. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 22:1999;51-61.
54. Xue R., Sawada M., Goto S., et al. Rapid three-dimensional diffusion MRI facilitates the study of acute stroke in mice. Magn. Reson. Med. 46:2001;183-188.
55. Zeevalk G.D., Derr-Yellin E., Nicklas W.J. NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid. J. Neurochem. 64:1995;455-458.
56. Zeevalk G.D., Derr-Yellin E., Nicklas W.J. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J. Pharmacol. Exp. Ther. 275:1995;1124-1130.